Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Immtech Puts Hold on Clinical Trials of Pafuramidine

publication date: Dec 26, 2007

Immtech Pharma put a hold on its Phase III clinical program for pafuramidine, a treatment for pneumocystis pneumonia (PCP) (an HIV/AIDS related illness) and African sleeping sickness. Immtech is conducting worldwide trials of pafuramidine and recently added a China arm. The drug was given Fast Track status by the SFDA earlier this year. In South African labs, observers noted that trial volunteers had abnormally high liver toxicity readings. More details...

Stock Symbol: (AMEX: IMM)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital